Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current and emerging lupus treatments.

D Wallace

    The American Journal of Managed Care
    |October 30, 2001
    PubMed
    Summary
    This summary is machine-generated.

    New immunomodulating therapies, including prasterone, offer hope for treating mild-to-moderate lupus, potentially reducing steroid dependence. Advanced treatments, like biologic agents, are also emerging for severe systemic lupus erythematosus.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Association, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, Vancouver, BC, Sept. 17-21, 2013.

    Canadian journal of surgery. Journal canadien de chirurgie·2025
    Same author

    Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis.

    Allergy·2023
    Same author

    Trend analysis and prediction of seasonal changes in milk composition from a pasture-based dairy research herd.

    Journal of dairy science·2023
    Same author

    Choosing wisely in burn care.

    Burns : journal of the International Society for Burn Injuries·2021
    Same author

    Meta-analyses of the efficacy of pharmacotherapies and sublingual allergy immunotherapy tablets for allergic rhinitis in adults and children.

    Rhinology·2021
    Same author

    Genome-wide surveillance of transcription errors in response to genotoxic stress.

    Proceedings of the National Academy of Sciences of the United States of America·2021
    Same journal

    Prescription drug prior authorization: costs to pharmacies and physicians.

    The American journal of managed care·2026
    Same journal

    Combined pharmacotherapy and psychotherapy impact on opioid use disorder treatment.

    The American journal of managed care·2026
    Same journal

    The societal costs of food insecurity: implications for managed care strategies.

    The American journal of managed care·2026
    Same journal

    Availability of hospital financial assistance documents in non-English languages.

    The American journal of managed care·2026
    Same journal

    Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

    The American journal of managed care·2026
    Same journal

    Social needs screening and supplemental benefits in Medicare Advantage.

    The American journal of managed care·2026
    See all related articles

    Area of Science:

    • Rheumatology
    • Immunology
    • Pharmacology

    Background:

    • Lupus treatment has seen limited advancements until recently.
    • Current treatments, particularly steroids, carry significant side effects and costs.
    • There is a need for novel therapeutic strategies for lupus management.

    Purpose of the Study:

    • To review recent developments in lupus treatment.
    • To highlight emerging immunomodulating therapies and biologic agents.
    • To discuss improvements in traditional lupus therapies.

    Main Methods:

    • Literature review of recent studies and clinical trials in lupus treatment.
    • Analysis of novel immunomodulating agents, including prasterone.
    • Evaluation of biologic agents and advancements in conventional therapies.

    Related Experiment Videos

    Main Results:

    • Synthetic dehydroepiandrosterone (prasterone) shows promise for mild-to-moderate lupus, potentially reducing steroid use.
    • Biologic agents represent a significant advancement for severe systemic lupus erythematosus.
    • Improvements in traditional therapies may offer additional benefits to patients.

    Conclusions:

    • New immunomodulating therapies and biologic agents are expected to improve lupus patient outcomes.
    • Prasterone may offer a steroid-sparing option for mild-to-moderate lupus.
    • Ongoing research and development promise better management of systemic lupus erythematosus.